The healthcare sector, explained: a map of the whole chain

Every year, the United States spends about $5.3 trillion on health — roughly 18% of its entire economy, or around $15,474 per person. Almost all of that money flows through a chain of companies you can study, and many of them you can invest in. That is what the healthcare sector is: not hospitals alone, not drug companies alone, but the whole chain that turns scientific research into a treatment, delivers it to a patient, and pays the bill.

This series walks that chain end to end. This first piece is the map. By the end you will know what a "sector" is, why healthcare is called defensive, how the nine links fit together, and — because most readers here are not American — which parts of this are universal and which are quirks of the US system.

Where this sits: the whole chain at a glance

Think of healthcare as a value chain you can read from left to right — from the lab bench, to the bedside, to the bill:

Discovery → Frontier → Tools → Devices → Providers → Payers → Middlemen

Each link is a different kind of business that behaves in a different way, and each gets its own article:

• The Discovery — big pharmaceutical companies that invent and sell medicines. Cash-rich and steady, but every drug is a patent on a timer.
• The Frontier — biotech: smaller, younger, higher-risk companies whose fate can turn on a single trial result.
• The Tools — the "picks and shovels": the instruments, reagents, and tests the whole industry buys.
• The Devices — the physical hardware of care, from surgical robots to glucose monitors.
• The Providers — the hospitals and clinics that actually deliver treatment.
• The Payers — the insurers who fund care. This is the most US-specific link of all.
• The Middlemen — the distributors and pharmacy-benefit managers that move product and money between everyone else.
• The Forces — a closing look at what moves every link at once: demographics, innovation, and politics.

What a "sector" actually is

The stock market is often measured by an index such as the S&P 500 — a list of 500 of the largest companies listed in the US. Those companies are sorted into 11 groups of similar businesses, called sectors, under a system named GICS. Healthcare is one of them.

Think of sectors as the aisles of a supermarket: dairy in one, cleaning products in another. Grouping similar companies makes it easier to compare them and to see where money is flowing. Healthcare is consistently one of the two or three largest aisles — recently around 11% of the S&P 500's value [refresh: current sector weight], usually behind technology.

Why healthcare is called "defensive"

This is the single most important idea in the series. A defensive sector is one whose demand stays relatively stable whatever the economy does. You might delay buying a car in a downturn, but you do not stop taking blood-pressure medication. People get ill, age, and need care in a recession as much as in a boom.

That steadiness tends to make healthcare revenues more predictable, which is why investors often shift towards the sector when markets turn nervous. The trade-off: that same steadiness can mean healthcare lags when markets are racing ahead. In recent years it did exactly that — roughly flat in 2023 and 2024 while the broad market surged, then recovering more strongly in 2025. Defensive means steadier, not safer in every sense, and never risk-free.

One number you will keep meeting: the P/E

You will see the price-to-earnings ratio (P/E) throughout. In plain terms, it compares a company's price to its profits — a rough gauge of how expensive it is for what it earns. A higher P/E usually means investors expect strong growth; a lower one can mean caution, or a bargain, or both. Healthcare has often traded at a more modest valuation than the hottest growth sectors — its forward P/E sat in the high-teens (~17x) in early 2026 [refresh]. You do not need to memorise that; just remember that what you pay is always part of the story, separate from how good the business is.

If you are not in the US (most of you)

This series leans on the US deliberately — it is the world's largest healthcare market by a wide margin, and most of the biggest, most influential healthcare companies are listed there. But a few things matter if you are reading from outside America, and they will recur in every article:

• The companies are global even when the listing is American. A US-listed drugmaker sells its products in your country too. Understanding it does not require being American.
• The US system is unusual. The heavy role of private insurers and pharmacy middlemen (the Payers and Middlemen links) barely exists elsewhere. Treat those as a study of how those companies make money, not how healthcare works where you live.
• Access, tax, and currency differ. What a US investor can buy, and how they are taxed, may not match your options — and a US-listed holding's value to you also moves with the exchange rate. Anything that reads like a practical "how to" should be checked against your own country's rules and a locally regulated professional.

The takeaways

• A sector is a group of similar companies; healthcare is one of 11, and one of the largest — recently around 11% of the S&P 500.
• The US spends $5.3 trillion (18% of GDP) on health each year, and almost all of it runs through a chain of listed companies.
• Healthcare is defensive: steadier demand, which can cushion downturns and dampen rallies.
• The sector is not one thing — it spans steady insurers, cash-rich drugmakers, and high-risk early biotech, all of which behave differently.
• We focus on the US because it is the biggest market, but watch for system quirks, currency, and access differences if you are elsewhere.

The tour starts at the first link in the chain: the companies that actually invent the medicines. Next, The Discovery.

This article is for information only and is not investment advice or a recommendation to buy or sell any security. [Publication] is not a licensed financial adviser. Figures are accurate as of June 2026 and will change. Markets carry risk, including loss of capital. Rules, taxes, and available products differ by country — do your own research and consider a locally regulated professional.